Condition
Advanced Stage Solid Tumors
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07107230Phase 1RecruitingPrimary
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
NCT06255665Phase 1CompletedPrimary
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
NCT03309150Phase 1CompletedPrimary
ATRi Transition Rollover Study
NCT02160106Phase 1CompletedPrimary
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
Showing all 4 trials